MaxCyte (MXCT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Election of three nominees as Class II directors: Patrick J. Balthrop, Cynthia Collins, and Stanley C. Erck for the board.
Ratification of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and the auditor ratification.
Audit committee and external auditor matters
Audit Committee has selected CohnReznick LLP as the independent auditor for the upcoming fiscal year.
Shareholders are asked to ratify this selection at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MaxCyte
- Q1 2025 revenue fell 8% to $10.4M, but core business grew and guidance is reaffirmed.MXCT
Q1 20259 Jul 2026 - Q2 2024 revenue up 15% to $10.4M, SPL revenue surged 279%, and cash guidance raised to $180M.MXCT
Q2 20249 Jul 2026 - Q3 revenue rose 2% to $8.2M, core revenue up 23%, and six new SPLs set a record.MXCT
Q3 20249 Jul 2026 - Restructuring, SecureDx integration, and new launches set the stage for global growth in 2026.MXCT
Stephens Annual Investment Conference8 Jul 2026 - Electroporation and SPL growth drive strong momentum in cell and gene therapy markets.MXCT
Stifel 2024 Healthcare Conference8 Jul 2026 - 2025 guidance targets 8–15% core revenue growth and $5M SPL revenue, leveraging SeQure Dx.MXCT
Q4 20248 Jul 2026 - Q1 2026 revenue fell 7%, net loss narrowed, and a $10M share repurchase was authorized.MXCT
Q1 202613 May 2026 - Election of directors and auditor ratification highlight governance and compensation practices.MXCT
Proxy filing29 Apr 2026 - 2025 revenue fell 15%, but cost cuts and new launches set up a back-half 2026 recovery.MXCT
Q4 202527 Mar 2026